News

Public · Published

Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $409.38, Implies 28% Upside

The average 12-month price target for Krystal Biotech stock from 8 analysts rose to $409.38 from $395.44, with forecasts ranging from $361 to $474. Based on the Oct. 27 closing price, the target implies about 28% upside.

Published:

Updated:

What happened

The average 12-month price target for Krystal Biotech stock from 8 analysts rose to $409.38 from $395.44, with forecasts ranging from $361 to $474. Based on the Oct. 27 closing price, the target implies about 28% upside.

Confirmed

Global impact / market context

A higher average target means analysts on balance expect more gains than before, which can draw buyers toward the stock. For existing holders, it offers reassurance that professional forecasts still lean positive, though targets are opinions rather than guarantees.

Analyst inference

Consensus rating stands at Buy across 12 analysts: 11 Buys, 1 Hold and 0 Sells. That near-unanimous stance suggests analysts see the company's prospects favorably, while the $361–$474 range shows they disagree on how much upside is realistic.

Analyst inference

What to watch

  1. Watch whether the average target keeps rising or reverses, since it moved from $395.44 to $409.38 across 8 analysts. Confirmed
  2. Watch for new analyst notes or rating changes, because the current Buy consensus of 11 Buys and 1 Hold could shift if views on the company change. Proposed
  3. Track the actual share price against the $409.38 target and the $361–$474 range, since a narrowing gap would mean less remaining upside. Analyst inference

Evidence

  • Original source link unavailable